146 related articles for article (PubMed ID: 10593938)
1. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.
Kuhns JJ; Batalia MA; Yan S; Collins EJ
J Biol Chem; 1999 Dec; 274(51):36422-7. PubMed ID: 10593938
[TBL] [Abstract][Full Text] [Related]
2. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts.
Sharma AK; Kuhns JJ; Yan S; Friedline RH; Long B; Tisch R; Collins EJ
J Biol Chem; 2001 Jun; 276(24):21443-9. PubMed ID: 11287414
[TBL] [Abstract][Full Text] [Related]
3. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
[TBL] [Abstract][Full Text] [Related]
4. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
[TBL] [Abstract][Full Text] [Related]
5. MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules.
Di Modugno F; Mammi C; Rosanò L; Rubiu O; Nisticò P; Chersi A
J Immunother; 1997 Nov; 20(6):431-6. PubMed ID: 9409448
[TBL] [Abstract][Full Text] [Related]
6. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
7. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
8. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
Alexander-Miller MA; Parker KC; Tsukui T; Pendleton CD; Coligan JE; Berzofsky JA
Int Immunol; 1996 May; 8(5):641-9. PubMed ID: 8671651
[TBL] [Abstract][Full Text] [Related]
11. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
12. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues.
Harig S; Witzens M; Krackhardt AM; Trojan A; Barrett P; Broderick R; Zauls AJ; Gribben JG
Blood; 2001 Nov; 98(10):2999-3005. PubMed ID: 11698283
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the interaction of the human cytomegalovirus-derived US2 protein with major histocompatibility complex class I molecules: prominent role of a single arginine residue in human leukocyte antigen-A2.
Thilo C; Berglund P; Applequist SE; Yewdell JW; Ljunggren HG; Achour A
J Biol Chem; 2006 Mar; 281(13):8950-7. PubMed ID: 16452487
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
Henle AM; Erskine CL; Benson LM; Clynes R; Knutson KL
J Immunol; 2013 Jan; 190(1):479-88. PubMed ID: 23180824
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
17. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
18. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
19. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for clonal diversity of the human T-cell response to a dominant influenza virus epitope.
Yang X; Chen G; Weng NP; Mariuzza RA
J Biol Chem; 2017 Nov; 292(45):18618-18627. PubMed ID: 28931605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
